COLLABORATE El Meu Clínic . This link opens in a new tab.
Search
COLLABORATE El Meu Clínic . This link opens in a new tab.
Navigation thread
Sergio Navarro

Sergio Navarro

Research group

//orcid.org/0000-0002-5565-4218 0000-0002-5565-4218

About me

I’ve started my career in science when I started my degree in in Biochemistry from the University of the Balearic Islands, where I received scholarships for academic excellence through the Ramón Areces Foundation for 4 consecutive years. During these years I’ve made different collaborations in the Laboratory in Physical Activity Sciences and the research group in Community Nutrition and Oxidative Stress, both from this university, where I developed my final degree project related to immunology and inflammation called “Associated inflammation marker response to regular and acute physical exercise”. After this I decided to take the entrance exam for specialized health training, where I chose a place at the Bellvitge University Hospital specializing in Immunology. I have extensive knowledge i

Featured publications

  • Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept

    Authors:
    Navarro Velázquez; Sergio;
    Reference: Frontiers In Immunology 2022.

  • Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy

    Authors:
    Navarro Velázquez; Sergio;
    Reference: Frontiers In Immunology 2022.

  • Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona

    Authors:
    Navarro Velázquez; Sergio;
    Reference: Journal Of Clinical Immunology 2021.

  • Clinical, randomized, double blind clinical trial to study the effect of parenteral supplementation with fish oil emulsion in the nutritional support in esophagectomized patients

    Authors:
    Navarro Velázquez; Sergio;
    Reference: Medicine 2021.

Featured Projects

  • BDCA-3 cross-priming dendritic cell vaccines in an immunotherapy strategy for refractory urothelial and renal carcinomas (ITvacur)

    Funder: Instituto de Investigación Sanitaria de Navarra (IdiSNA) (Sede o evento)
    Code: ICI22/00115
    Duration: 01/01/2023

  • Seguridad y eficacia de la terapia hCD1a-CAR T (OC-1), en pacientes con leucemia/linfoma linfoblástico agudo de células T (T-ALL/LL) en recaída/refractario (R/R).

    Principal investigator: Pablo Menéndez
    Funder: HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA (Sede o evento); OneChain Immunotherapeutics ; HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA; Hospital Sant Joan de Déu (Participante)
    Duration: 01/01/2023

  • Artificial Intelligence-driven, Decentralized Production for Advanced Therapies in the Hospital

    Principal investigator: Simon Hort
    Funder: FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Sede o evento); AGLARIS CELL SL; FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.; FUJIFILM EUROPE BV; FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA; IDRYMA TECHNOLOGIAS KAI EREVNAS; IRIS TECHNOLOGY SOLUTIONS, SOCIEDAD LIMITADA; ORTEC OPTIMIZATION TECHNOLOGY BV; PANAXEA BV; RED ALERT LABS; SZAMITASTECHNIKAI ES AUTOMATIZALASI KUTATOINTEZET; UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT; UNIVERSITY COLLEGE LONDON (Participante)
    Code: 101016909
    Duration: 01/01/2021 - 31/12/2024